Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
暂无分享,去创建一个
[1] A. Loft,et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry , 2012, Annals of the rheumatic diseases.
[2] D. Solomon,et al. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. , 2013, Arthritis and rheumatism.
[3] M. Suarez‐Almazor,et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.
[4] E. Rahme,et al. Melanoma and rheumatoid arthritis (brief report) , 2012, Clinical Rheumatology.
[5] Hana Jeon,et al. Letter: Methotrexate for localized morphea with severe pain: a case report. , 2011, Dermatology Online Journal.
[6] P. Calzavara-Pinton,et al. Cutaneous melanoma in patients in treatment with biological therapy: review of the literature and case report. , 2011, Dermatology Online Journal.
[7] T. Torres,et al. Letter: Penile Kaposi sarcoma: A case of complete resolution with highly active antiretroviral therapy alone. , 2011, Dermatology Online Journal.
[8] A. Eggermont,et al. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha , 2011, Current opinion in oncology.
[9] D. Symmons,et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data , 2011, Pharmacoepidemiology and drug safety.
[10] M. Neovius,et al. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden , 2010, Annals of the rheumatic diseases.
[11] M. Neovius,et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register , 2010, Annals of the rheumatic diseases.
[12] U. Trefzer,et al. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma , 2011, Journal of Cancer Research and Clinical Oncology.
[13] A. Silman,et al. Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .
[14] J. Neuberger,et al. Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[15] W. Dixon,et al. SPECIAL ARTICLE: DRUG SAFETY IN THE RHEUMATIC DISEASES Influence of Anti–Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With Rheumatoid Arthritis Who Have Had a Prior Malignancy: Results From the British Society for Rheumatology , 2022 .
[16] N. Stavrianeas,et al. Development of Two Primary Malignant Melanomas after Treatment with Adalimumab: A Case Report and Review of the Possible Link between Biological Therapy with TNF-α Antagonists and Melanocytic Proliferation , 2010, Dermatology.
[17] Victor R. Preedy,et al. International Classification of Disease , 2010 .
[18] L. Jacobsson,et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? , 2009, Arthritis and rheumatism.
[19] L. Holmberg,et al. The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.
[20] E. Matteson,et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials , 2008, Annals of the rheumatic diseases.
[21] T. Einarson,et al. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.
[22] A. Eggermont,et al. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[23] M. Mihm,et al. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. , 2009, Cancer immunity.
[24] G. Giles,et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. , 2008, Arthritis and rheumatism.
[25] M. Herlyn,et al. Melanoma stem cells: the dark seed of melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Farmer,et al. Risk of skin cancer in the drug treatment of rheumatoid arthritis. , 2008, Expert opinion on drug safety.
[27] F. Wolfe,et al. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. , 2007, Arthritis and rheumatism.
[28] M. Falster,et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.
[29] Anders Sundström,et al. The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.
[30] J. Drabick,et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. , 2007, Journal of the American Academy of Dermatology.
[31] J. Kaldor,et al. Cancer incidence before and after kidney transplantation. , 2006, JAMA.
[32] J. Avorn,et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[33] K. Alam,et al. The treatment of melanoma with an emphasis on immunotherapeutic strategies. , 2006, Surgical oncology.
[34] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[35] P. Hwu,et al. Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention , 2006, Clinical Cancer Research.
[36] A. Iliadou,et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[37] H. Comber,et al. A population‐based study of skin cancer incidence and prevalence in renal transplant recipients , 2006, The British journal of dermatology.
[38] L. Klareskog,et al. Swedish registers to examine drug safety and clinical issues in RA , 2006, Annals of the rheumatic diseases.
[39] J. Avorn,et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[40] B. Kasiske,et al. Cancer after Kidney Transplantation in the United States , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[41] P. Carli,et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. , 2003, Journal of the American Academy of Dermatology.
[42] G. Macfarlane,et al. Risk of malignancy among patients with rheumatic conditions , 2000, International journal of cancer.
[43] S. Tóth,et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.
[44] J. Olsen,et al. Rheumatoid arthritis and cancer risk. , 1996, European journal of cancer.
[45] N. Chakraborty,et al. Immunobiology and immunotherapy of melanoma , 1995, Current opinion in oncology.
[46] J. F. Fraumeni,et al. Incidence of cancer among patients with rheumatoid arthritis. , 1993, Journal of the National Cancer Institute.